{"success":true,"data":{"pressRelease":{"id":"144685","rtpr_id":"nBw4Q9gvca-20260916","ticker":"GALD","exchange":"","all_tickers":["GALD"],"title":"Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing","author":"Business Wire","published_at":"2026-09-16T05:00:00.139Z","article_body":"Galderma’s Restylane(®) Volyme™ Demonstrates High Effectiveness,\nSatisfaction and a Robust Safety Profile in Chinese Patients With Temple\nHollowing\n\n\n * Positive topline results showed that Restylane Volyme (known as Restylane\nContour in the U.S.) was highly effective in the correction of\nmoderate-to-severe temple hollowing, with high responder rates maintained\nthrough Month 12(1)\n\n * Restylane Volyme was well tolerated, with no incidences of granulomas. Patient\nand investigator satisfaction were also high(1)\n\n * These data support Galderma’s aim to expand the availability of the\nRestylane portfolio in China – a market undergoing significant expansion,\nand further strengthen Restylane’s vast clinical evidence base(2,3)\n\nGalderma (SIX: GALD) today announced positive topline results from a study of\nRestylane Volyme for the correction of moderate-to-severe temple hollowing in\n162 patients in China.(1) The study met its primary endpoint, demonstrating\nthe effectiveness and safety of Restylane Volyme versus a no-treatment\ncontrol, while also achieving high patient and investigator satisfaction.(1)\nThese data further reinforce Galderma's ambition to expand its Restylane\nhyaluronic acid (HA) injectables portfolio in China, one of the world's\nfastest-growing aesthetics markets, through evidence generation that supports\nbroader patient access and additional treatment areas.(1-3)\n\nPowered by diverse NASHA(®), NASHA HD™, and OBT™ technologies, Restylane\noffers gels with the highest firmness to the highest flexibility, enabling\npersonalized treatments that deliver structural support, natural-looking\nresults, and a healthy glow.(1,4-8) Restylane Volyme is a moderately soft and\nflexible gel made with OBT that distributes within the tissue to offer\nnatural-looking results, helping to soften temple hollowing, restore facial\nbalance, and create a refreshed appearance.(1,4,9) With a dual-layer\npatent-pending technique leveraging both needle and cannula, Restylane Volyme\nenables healthcare professionals to provide precise, customized, and safe\nproduct placement in line with each patient’s aesthetic goals(10-12)\n\nThe volume of the temples can diminish with age, which can disrupt facial\nbalance and harmony, and contribute to a tired, sunken, and aged\nappearance.(12-14) These facial changes can be accelerated in people\nundergoing medication-driven weight loss, a phenomenon which has increased\nrapidly in recent years.(12-14) Following the launch of Restylane Volyme in\nChina for the treatment of the mid-face region, this study provides new\nevidence supporting its effectiveness and safety for correction of temple\nhollowing, in a market where there are currently limited options.(1)\n\n“Temple hollowing is a common concern among patients seeking facial\nrejuvenation, particularly for those experiencing medication-driven weight\nloss, yet treatment options in China remain limited. These results demonstrate\nthat Restylane Volyme can provide effective, natural-looking correction with\nhigh levels of patient satisfaction and a robust safety profile. As demand for\nindividualized aesthetic treatments continues to grow in China, expanding the\nrange of evidence-based solutions available will be increasingly important.”\n\nPROF. ZHAO HONGYI\n\nSTUDY PRINCIPAL INVESTIGATOR,\n\nDIRECTOR & CHIEF OF THE DEPARTMENT OF PLASTIC SURGERY, BEIJING HOSPITAL,\nCHINA\n\nIn this randomized, evaluator-blinded study, 162 adults were recruited across\nsix sites in China and were split 2:1 into two groups; the Restylane Volyme\ntreatment group or the no treatment control group.(1) Results showed that for\npatients in the Restylane Volyme group:\n\n\n * Strong effectiveness\n\n\n* 94.4% of patients demonstrated at least 1-grade improvement in temple\nhollowing, from baseline, in both temples at Month 6 after last treatment,\ncompared to just 2.0% in the control group at Month 6 after baseline.(1)\n\n * Blinded-evaluator Galderma Temple Volume Deficit Scale responder rates\nremained high through Month 12(1)\n\n * 91.3% of patients showed improvement on the Global Aesthetic Improvement Scale\nfor both temples through Month 12, according to the treating investigator(1)\n\n\n\n\n * High satisfaction\n\n\n* Patient satisfaction was high at Month 3 and remained consistently high,\nwith\nmore than 84% of patients satisfied with both the natural look and natural\nfeel of their temples through Month 12(1)\n\n * More than 90% said they would recommend the treatment to a friend, and over\n86% would have the treatment again(1)\n\n * Half of the participants felt comfortable returning to social engagement\nwithin 24 hours after initial treatment(1)\n\n\n\n\n * Robust safety\n\n\n* Restylane Volyme was generally well tolerated, with no treatment-related\nserious adverse events and no granulomas(1)\n\n\n\n\n“These positive topline results further strengthen the clinical evidence\nsupporting Restylane Volyme and mark an important step in our strategy to\nexpand the Restylane portfolio in China. As one of the world’s\nfastest-growing aesthetics markets, China presents a significant opportunity\nto address evolving patient needs with science-backed, differentiated\nsolutions. This study supports our ambition to broaden the indications\navailable to practitioners and patients, while reinforcing Galderma’s\nleadership in Injectable Aesthetics through continued investment in innovation\nand clinical research.”\n\nBALDO SCASSELLATI SFORZOLINI, M.D., PH.D.\n\nGLOBAL HEAD OF R&D\n\nGALDERMA\n\nWith over 30 years of innovation and more than 77 million treatments\nadministered worldwide, the Restylane portfolio offers a versatile range of HA\ngels that remain highly relevant in responding to today’s most significant\naesthetic trends and needs.(15-16) China is one of the fastest growing\naesthetics markets worldwide and HA fillers are among the top 10 most-sold\naesthetics products.(2,3) This study highlights Galderma’s commitment to\nexpand the availability of its Restylane portfolio to more patients and\npractitioners in China and exemplifies its continuing expansion in a growing\nand strategically significant market.\n\nAbout the Restylane portfolio\n\nRestylane HA treatments are designed differently to go beyond volumizing for\nnatural-looking results.(17-19 )Our HA is minimally modified and our\ninnovative manufacturing process preserves its biocompatibility while creating\nindividual products designed for a specific purpose.(5,20,21 )Powered by\nNASHA(®), NASHA HD™, and OBT™ technologies, Restylane offers gels with\nthe highest firmness to the highest flexibility, enabling personalized\ntreatments that deliver structural support, natural-looking results, and a\nhealthy glow.(4,6-8 )Trusted for almost three decades, our HA gels work in\nsync with your skin for 100% natural-looking results.( 18,22,23) Approved\nindications vary by market.\n\nAbout Galderma\n\nGalderma (SIX: GALD) is the pure-play dermatology category leader, present in\napproximately 90 countries. We deliver an innovative, science-based portfolio\nof premium flagship brands and services that span the full spectrum of the\nfast-growing dermatology market through Injectable Aesthetics, Dermatological\nSkincare and Therapeutic Dermatology. Since our foundation in 1981, we have\ndedicated our focus and passion to the human body’s largest organ – the\nskin – meeting individual consumer and patient needs with superior outcomes\nin partnership with healthcare professionals. Because we understand that the\nskin we are in shapes our lives, we are advancing dermatology for every skin\nstory. For more information: www.galderma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.galderma.com%2F&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=www.galderma.com&index=1&md5=6f3825964c95abef72143032144f59df)\n.\n\nReferences\n\n\n 1. Galderma. Data on file. 43CH2401\n\n 2. Deloitte. China Aesthetic Medicine Outlook Report. Accessed September 2026.\nAvailable \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.deloitte.com%2Fcn%2Fzh%2FIndustries%2Flife-sciences-health-care%2Fperspectives%2Fchina-medical-aesthetic-industry-outlook-2025.html&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=online&index=2&md5=8a984803edc6dd1bdba24886cb378a50)\n\n.\n\n 3. Grand View Horizon. China Aesthetic Medicine Market Size & Outlook,\n2026-2033. Accessed September 2026. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.grandviewresearch.com%2Fhorizon%2Foutlook%2Faesthetic-medicine-market%2Fchina&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=online&index=3&md5=ab86923fb4da96bbd87f89f93a40c3cc)\n\n 4. Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´\nincluding Restylane SHAYPE).\n\n 5. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.\n\n 6. Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable\nfor Augmentation and Correction of Chin Retrusion. J Drugs Dermatol.\n2024;23(4):255–261. doi: 10.36849/JDD.8145.\n\n 7. Öhrlund Å, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels\nAccording to Strength, Flexibility, and Associated Clinical Significance. J\nDrugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.\n\n 8. Belmontesi M, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a\nSkin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol.\n2018;17(1):83–88.\n\n 9. Talarico S et al. High Patient Satisfaction of a Hyaluronic Acid Filler\nProducing Enduring Full-Facial Volume Restoration: An 18-Month Open\nMulticenter Study. Dermatol Surg. 2015;41(12):1361-9. doi:\n10.1097/DSS.0000000000000549\n\n 10. Restylane® Volyme. IFU. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fau%2Fsites%2Fdefault%2Ffiles%2Finline-files%2FIFU%2520Restylane%2520Volyme%2520English%2520March%25202020_0.pdf&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=online&index=4&md5=6ce2c3e73be6c4f69693d36e01ad16b4)\n\n. Accessed September 2026\n\n 11. Galderma Laboratories, L.P. Data on file. MA-63365 Study Report. 2025\n\n 12. Galderma. Data on file. Restylane Contour temple investigator closeout meeting\nexecutive summary. 2025\n\n 13. Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1\nreceptor agonists for facial plastic surgeons. Facial Plast Surg,\n2023;39:719-73. doi: 10.1055/a-2148-6321\n\n 14. Tay JQ. Ozempic face: A new challenge for facial plastic surgeons.\nJPRAS.2023;81-97-98. doi: 10.1016/j.bjps.2023.04.057\n\n 15. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.\n\n 16. Galderma. Data on file. MA-55607. Restylane(®) 27 years data publications\nanalysis\n\n 17. Restylane(®) EU Instructions for Use. July 2026.\n\n 18. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of\ninjectable HA fillers for facial aesthetic treatment. E-poster presented at\nAMWC; March 27-29, 2024; Monaco.\n\n 19. Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT\nFillers. 2021.\n\n 20. Kablik J, et al. Comparative physical properties of HA dermal fillers.\nDermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.\n\n 21. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol\nSurg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.\n\n 22. Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain\nnatural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi:\n10.1111/jocd.12961.\n\n 23. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after\nHA filler injection in nasolabial folds and lower face. J Cosmet Dermatol.\n2020;19(7):1600-1606. doi: 10.1111/jocd.1320\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260915734207/en/\n(https://www.businesswire.com/news/home/20260915734207/en/)\n\nFor further information:\n\nChristian Marcoux, M.Sc.\n\nChief Communications Officer\n\nchristian.marcoux@galderma.com \n(mailto:christian.marcoux@galderma.com) \n+41 76 315 26 50\n\nRichard Harbinson\n\nCorporate Communications Director\n\nrichard.harbinson@galderma.com \n(mailto:richard.harbinson@galderma.com) \n+41 76 210 60 62\n\nCéline Buguet\n\nFranchises and R&D Communications Director\n\nceline.buguet@galderma.com \n(mailto:celine.buguet@galderma.com) \n+41 76 249 90 87\n\nEmil Ivanov\n\nHead of Strategy, Investor Relations, and ESG\n\nemil.ivanov@galderma.com \n(mailto:emil.ivanov@galderma.com) \n+41 21 642 78 12\n\nJessica Cohen\n\nInvestor Relations and Strategy Director\n\njessica.cohen@galderma.com \n(mailto:jessica.cohen@galderma.com) \n+41 21 642 76 43\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw4Q9gvca-20260916","title":"Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing","author":"Business Wire","ticker":"GALD","created":"2026-09-16T05:00:00.139Z","tickers":["GALD"],"exchange":"","article_body":"Galderma’s Restylane(®) Volyme™ Demonstrates High Effectiveness,\nSatisfaction and a Robust Safety Profile in Chinese Patients With Temple\nHollowing\n\n\n * Positive topline results showed that Restylane Volyme (known as Restylane\nContour in the U.S.) was highly effective in the correction of\nmoderate-to-severe temple hollowing, with high responder rates maintained\nthrough Month 12(1)\n\n * Restylane Volyme was well tolerated, with no incidences of granulomas. Patient\nand investigator satisfaction were also high(1)\n\n * These data support Galderma’s aim to expand the availability of the\nRestylane portfolio in China – a market undergoing significant expansion,\nand further strengthen Restylane’s vast clinical evidence base(2,3)\n\nGalderma (SIX: GALD) today announced positive topline results from a study of\nRestylane Volyme for the correction of moderate-to-severe temple hollowing in\n162 patients in China.(1) The study met its primary endpoint, demonstrating\nthe effectiveness and safety of Restylane Volyme versus a no-treatment\ncontrol, while also achieving high patient and investigator satisfaction.(1)\nThese data further reinforce Galderma's ambition to expand its Restylane\nhyaluronic acid (HA) injectables portfolio in China, one of the world's\nfastest-growing aesthetics markets, through evidence generation that supports\nbroader patient access and additional treatment areas.(1-3)\n\nPowered by diverse NASHA(®), NASHA HD™, and OBT™ technologies, Restylane\noffers gels with the highest firmness to the highest flexibility, enabling\npersonalized treatments that deliver structural support, natural-looking\nresults, and a healthy glow.(1,4-8) Restylane Volyme is a moderately soft and\nflexible gel made with OBT that distributes within the tissue to offer\nnatural-looking results, helping to soften temple hollowing, restore facial\nbalance, and create a refreshed appearance.(1,4,9) With a dual-layer\npatent-pending technique leveraging both needle and cannula, Restylane Volyme\nenables healthcare professionals to provide precise, customized, and safe\nproduct placement in line with each patient’s aesthetic goals(10-12)\n\nThe volume of the temples can diminish with age, which can disrupt facial\nbalance and harmony, and contribute to a tired, sunken, and aged\nappearance.(12-14) These facial changes can be accelerated in people\nundergoing medication-driven weight loss, a phenomenon which has increased\nrapidly in recent years.(12-14) Following the launch of Restylane Volyme in\nChina for the treatment of the mid-face region, this study provides new\nevidence supporting its effectiveness and safety for correction of temple\nhollowing, in a market where there are currently limited options.(1)\n\n“Temple hollowing is a common concern among patients seeking facial\nrejuvenation, particularly for those experiencing medication-driven weight\nloss, yet treatment options in China remain limited. These results demonstrate\nthat Restylane Volyme can provide effective, natural-looking correction with\nhigh levels of patient satisfaction and a robust safety profile. As demand for\nindividualized aesthetic treatments continues to grow in China, expanding the\nrange of evidence-based solutions available will be increasingly important.”\n\nPROF. ZHAO HONGYI\n\nSTUDY PRINCIPAL INVESTIGATOR,\n\nDIRECTOR & CHIEF OF THE DEPARTMENT OF PLASTIC SURGERY, BEIJING HOSPITAL,\nCHINA\n\nIn this randomized, evaluator-blinded study, 162 adults were recruited across\nsix sites in China and were split 2:1 into two groups; the Restylane Volyme\ntreatment group or the no treatment control group.(1) Results showed that for\npatients in the Restylane Volyme group:\n\n\n * Strong effectiveness\n\n\n* 94.4% of patients demonstrated at least 1-grade improvement in temple\nhollowing, from baseline, in both temples at Month 6 after last treatment,\ncompared to just 2.0% in the control group at Month 6 after baseline.(1)\n\n * Blinded-evaluator Galderma Temple Volume Deficit Scale responder rates\nremained high through Month 12(1)\n\n * 91.3% of patients showed improvement on the Global Aesthetic Improvement Scale\nfor both temples through Month 12, according to the treating investigator(1)\n\n\n\n\n * High satisfaction\n\n\n* Patient satisfaction was high at Month 3 and remained consistently high,\nwith\nmore than 84% of patients satisfied with both the natural look and natural\nfeel of their temples through Month 12(1)\n\n * More than 90% said they would recommend the treatment to a friend, and over\n86% would have the treatment again(1)\n\n * Half of the participants felt comfortable returning to social engagement\nwithin 24 hours after initial treatment(1)\n\n\n\n\n * Robust safety\n\n\n* Restylane Volyme was generally well tolerated, with no treatment-related\nserious adverse events and no granulomas(1)\n\n\n\n\n“These positive topline results further strengthen the clinical evidence\nsupporting Restylane Volyme and mark an important step in our strategy to\nexpand the Restylane portfolio in China. As one of the world’s\nfastest-growing aesthetics markets, China presents a significant opportunity\nto address evolving patient needs with science-backed, differentiated\nsolutions. This study supports our ambition to broaden the indications\navailable to practitioners and patients, while reinforcing Galderma’s\nleadership in Injectable Aesthetics through continued investment in innovation\nand clinical research.”\n\nBALDO SCASSELLATI SFORZOLINI, M.D., PH.D.\n\nGLOBAL HEAD OF R&D\n\nGALDERMA\n\nWith over 30 years of innovation and more than 77 million treatments\nadministered worldwide, the Restylane portfolio offers a versatile range of HA\ngels that remain highly relevant in responding to today’s most significant\naesthetic trends and needs.(15-16) China is one of the fastest growing\naesthetics markets worldwide and HA fillers are among the top 10 most-sold\naesthetics products.(2,3) This study highlights Galderma’s commitment to\nexpand the availability of its Restylane portfolio to more patients and\npractitioners in China and exemplifies its continuing expansion in a growing\nand strategically significant market.\n\nAbout the Restylane portfolio\n\nRestylane HA treatments are designed differently to go beyond volumizing for\nnatural-looking results.(17-19 )Our HA is minimally modified and our\ninnovative manufacturing process preserves its biocompatibility while creating\nindividual products designed for a specific purpose.(5,20,21 )Powered by\nNASHA(®), NASHA HD™, and OBT™ technologies, Restylane offers gels with\nthe highest firmness to the highest flexibility, enabling personalized\ntreatments that deliver structural support, natural-looking results, and a\nhealthy glow.(4,6-8 )Trusted for almost three decades, our HA gels work in\nsync with your skin for 100% natural-looking results.( 18,22,23) Approved\nindications vary by market.\n\nAbout Galderma\n\nGalderma (SIX: GALD) is the pure-play dermatology category leader, present in\napproximately 90 countries. We deliver an innovative, science-based portfolio\nof premium flagship brands and services that span the full spectrum of the\nfast-growing dermatology market through Injectable Aesthetics, Dermatological\nSkincare and Therapeutic Dermatology. Since our foundation in 1981, we have\ndedicated our focus and passion to the human body’s largest organ – the\nskin – meeting individual consumer and patient needs with superior outcomes\nin partnership with healthcare professionals. Because we understand that the\nskin we are in shapes our lives, we are advancing dermatology for every skin\nstory. For more information: www.galderma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.galderma.com%2F&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=www.galderma.com&index=1&md5=6f3825964c95abef72143032144f59df)\n.\n\nReferences\n\n\n 1. Galderma. Data on file. 43CH2401\n\n 2. Deloitte. China Aesthetic Medicine Outlook Report. Accessed September 2026.\nAvailable \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.deloitte.com%2Fcn%2Fzh%2FIndustries%2Flife-sciences-health-care%2Fperspectives%2Fchina-medical-aesthetic-industry-outlook-2025.html&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=online&index=2&md5=8a984803edc6dd1bdba24886cb378a50)\n\n.\n\n 3. Grand View Horizon. China Aesthetic Medicine Market Size & Outlook,\n2026-2033. Accessed September 2026. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.grandviewresearch.com%2Fhorizon%2Foutlook%2Faesthetic-medicine-market%2Fchina&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=online&index=3&md5=ab86923fb4da96bbd87f89f93a40c3cc)\n\n 4. Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´\nincluding Restylane SHAYPE).\n\n 5. Galderma. Data on file. MA-58650. Degree of modification of HA fillers.\n\n 6. Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable\nfor Augmentation and Correction of Chin Retrusion. J Drugs Dermatol.\n2024;23(4):255–261. doi: 10.36849/JDD.8145.\n\n 7. Öhrlund Å, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels\nAccording to Strength, Flexibility, and Associated Clinical Significance. J\nDrugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.\n\n 8. Belmontesi M, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a\nSkin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol.\n2018;17(1):83–88.\n\n 9. Talarico S et al. High Patient Satisfaction of a Hyaluronic Acid Filler\nProducing Enduring Full-Facial Volume Restoration: An 18-Month Open\nMulticenter Study. Dermatol Surg. 2015;41(12):1361-9. doi:\n10.1097/DSS.0000000000000549\n\n 10. Restylane® Volyme. IFU. Available \nonline\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.galderma.com%2Fau%2Fsites%2Fdefault%2Ffiles%2Finline-files%2FIFU%2520Restylane%2520Volyme%2520English%2520March%25202020_0.pdf&esheet=54603201&newsitemid=20260915734207&lan=en-US&anchor=online&index=4&md5=6ce2c3e73be6c4f69693d36e01ad16b4)\n\n. Accessed September 2026\n\n 11. Galderma Laboratories, L.P. Data on file. MA-63365 Study Report. 2025\n\n 12. Galderma. Data on file. Restylane Contour temple investigator closeout meeting\nexecutive summary. 2025\n\n 13. Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1\nreceptor agonists for facial plastic surgeons. Facial Plast Surg,\n2023;39:719-73. doi: 10.1055/a-2148-6321\n\n 14. Tay JQ. Ozempic face: A new challenge for facial plastic surgeons.\nJPRAS.2023;81-97-98. doi: 10.1016/j.bjps.2023.04.057\n\n 15. Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.\n\n 16. Galderma. Data on file. MA-55607. Restylane(®) 27 years data publications\nanalysis\n\n 17. Restylane(®) EU Instructions for Use. July 2026.\n\n 18. Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of\ninjectable HA fillers for facial aesthetic treatment. E-poster presented at\nAMWC; March 27-29, 2024; Monaco.\n\n 19. Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT\nFillers. 2021.\n\n 20. Kablik J, et al. Comparative physical properties of HA dermal fillers.\nDermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.\n\n 21. Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol\nSurg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.\n\n 22. Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain\nnatural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi:\n10.1111/jocd.12961.\n\n 23. Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after\nHA filler injection in nasolabial folds and lower face. J Cosmet Dermatol.\n2020;19(7):1600-1606. doi: 10.1111/jocd.1320\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260915734207/en/\n(https://www.businesswire.com/news/home/20260915734207/en/)\n\nFor further information:\n\nChristian Marcoux, M.Sc.\n\nChief Communications Officer\n\nchristian.marcoux@galderma.com \n(mailto:christian.marcoux@galderma.com) \n+41 76 315 26 50\n\nRichard Harbinson\n\nCorporate Communications Director\n\nrichard.harbinson@galderma.com \n(mailto:richard.harbinson@galderma.com) \n+41 76 210 60 62\n\nCéline Buguet\n\nFranchises and R&D Communications Director\n\nceline.buguet@galderma.com \n(mailto:celine.buguet@galderma.com) \n+41 76 249 90 87\n\nEmil Ivanov\n\nHead of Strategy, Investor Relations, and ESG\n\nemil.ivanov@galderma.com \n(mailto:emil.ivanov@galderma.com) \n+41 21 642 78 12\n\nJessica Cohen\n\nInvestor Relations and Strategy Director\n\njessica.cohen@galderma.com \n(mailto:jessica.cohen@galderma.com) \n+41 21 642 76 43\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-16T05:00:00.211611799Z","server_sent_at_ms":1789534800211},"received_at":"2026-09-16T05:00:00.363Z","source_url":"https://www.businesswire.com/news/home/20260915734207/en/"},"analysis":{"id":"133519","press_release_id":"144685","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Data are company-sponsored topline results (data on file), not peer-reviewed","Temple hollowing indication expansion in China is stated as an ambition; no regulatory approval announced in this release"],"eventType":"clinical_trial","narrative":"Galderma reported positive topline results from a 162-patient, randomized, evaluator-blinded study of Restylane Volyme for moderate-to-severe temple hollowing in China, with the trial meeting its primary endpoint versus a no-treatment control.\n\nAt Month 6, 94.4% of treated patients showed at least a 1-grade improvement in both temples versus 2.0% of controls, and 91.3% improved on the Global Aesthetic Improvement Scale through Month 12. The gel was generally well tolerated with no treatment-related serious adverse events and no granulomas, while more than 84% of patients remained satisfied with the natural look and feel through Month 12.\n\nThe data underpin Galderma's strategy to expand the Restylane portfolio in China, one of the world's fastest-growing aesthetics markets, and address temple hollowing linked to medication-driven weight loss, where treatment options remain limited.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Positive China data position Restylane Volyme for temple-hollowing indication expansion, tapping GLP-1 weight-loss-driven facial volume demand."},"keyFigures":{"drugName":"Restylane Volyme (known as Restylane Contour in the U.S.)","customDimensions":{"patients":162,"study_sites":6,"control_rate_month6":"2.0%","responder_rate_month6":"94.4%","would_repeat_treatment":"over 86%","galderma_country_presence":"approximately 90 countries","would_recommend_treatment":"more than 90%","restylane_treatments_worldwide":"77 million","gais_improvement_through_month12":"91.3%","patient_satisfaction_natural_look_feel_month12":"more than 84%"}},"quotedText":"These positive topline results further strengthen the clinical evidence\nsupporting Restylane Volyme and mark an important step in our strategy to\nexpand the Restylane portfolio in China.","namedEntities":{"people":[{"name":"Prof. Zhao Hongyi","role":"Study Principal Investigator; Director & Chief of the Department of Plastic Surgery, Beijing Hospital, China"},{"name":"Baldo Scassellati Sforzolini, M.D., Ph.D.","role":"Global Head of R&D, Galderma"}],"products":["Restylane Volyme","Restylane Contour","NASHA","NASHA HD","OBT"],"companies":[{"name":"Galderma","ticker":"GALD","relationship":"filer / study sponsor"},{"name":"Beijing Hospital","relationship":"study site / principal investigator affiliation"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Positive topline data from a company-sponsored 162-patient China study for an already-launched filler, supporting an indication-expansion ambition in a fast-growing market. Non-binary readout with no approval or revenue attached, so it is a supportive strategic catalyst rather than a market-moving event."},"tickerRelevance":{"others":[],"primary":"GALD"},"globalImportance":26,"audienceRelevance":30,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"large-cap Swiss-listed pure-play dermatology leader","eventGravity":"positive non-binary clinical topline for already-marketed product","sectorWeight":"aesthetics/dermatology — China expansion strategically relevant","marketCapAdjustment":"established global issuer but data readout lacks revenue or approval catalyst","retailFavoriteBoost":"modest GLP-1/Ozempic-face adjacency angle"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Galderma reported positive topline results from a 162-patient, randomized, evaluator-blinded study of Restylane Volyme for moderate-to-severe temple hollowing in China, with the trial meeting its primary endpoint versus a no-treatment control.\n\nAt Month 6, 94.4% of treated patients showed at least a 1-grade improvement in both temples versus 2.0% of controls, and 91.3% improved on the Global Aesthetic Improvement Scale through Month 12. The gel was generally well tolerated with no treatment-related serious adverse events and no granulomas, while more than 84% of patients remained satisfied with the natural look and feel through Month 12.\n\nThe data underpin Galderma's strategy to expand the Restylane portfolio in China, one of the world's fastest-growing aesthetics markets, and address temple hollowing linked to medication-driven weight loss, where treatment options remain limited.","key_figures":{"drugName":"Restylane Volyme (known as Restylane Contour in the U.S.)","customDimensions":{"patients":162,"study_sites":6,"control_rate_month6":"2.0%","responder_rate_month6":"94.4%","would_repeat_treatment":"over 86%","galderma_country_presence":"approximately 90 countries","would_recommend_treatment":"more than 90%","restylane_treatments_worldwide":"77 million","gais_improvement_through_month12":"91.3%","patient_satisfaction_natural_look_feel_month12":"more than 84%"}},"named_entities":{"people":[{"name":"Prof. Zhao Hongyi","role":"Study Principal Investigator; Director & Chief of the Department of Plastic Surgery, Beijing Hospital, China"},{"name":"Baldo Scassellati Sforzolini, M.D., Ph.D.","role":"Global Head of R&D, Galderma"}],"products":["Restylane Volyme","Restylane Contour","NASHA","NASHA HD","OBT"],"companies":[{"name":"Galderma","ticker":"GALD","relationship":"filer / study sponsor"},{"name":"Beijing Hospital","relationship":"study site / principal investigator affiliation"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T05:00:41.377Z","global_importance":26,"audience_relevance":30,"importance_components":{"tickerTier":"large-cap Swiss-listed pure-play dermatology leader","eventGravity":"positive non-binary clinical topline for already-marketed product","sectorWeight":"aesthetics/dermatology — China expansion strategically relevant","marketCapAdjustment":"established global issuer but data readout lacks revenue or approval catalyst","retailFavoriteBoost":"modest GLP-1/Ozempic-face adjacency angle"}},"durationMs":41004,"modelName":"glm-5.3-flash"}}